Get the Stockscreener App
2.59
14.60%
0.33
Pre-market:
2.60
0.01
+0.39%
Clearmind Medicine Inc stock is traded at $2.59, with a volume of 324.97K.
It is up +14.60% in the last 24 hours and down -68.10% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$2.26
Open:
$2.3
24h Volume:
324.97K
Relative Volume:
0.58
Market Cap:
$2.64M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.1433
EPS:
-18.0702
Net Cash Flow:
$-5.60M
1W Performance:
+9.61%
1M Performance:
-68.10%
6M Performance:
-95.83%
1Y Performance:
-99.33%
1-Day Range:
$2.28
$2.698
1-Week Range:
$2.10
$2.698
52-Week Range:
$2.10
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.59 | 2.30M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind receives Johns Hopkins IRB approval for trial parts - Investing.com UK
Clearmind Medicine Advances Cmnd-100 Phase I/Ii Clinical Trial to Next Parts - marketscreener.com
Clearmind receives Johns Hopkins IRB approval for trial parts By Investing.com - Investing.com Australia
Clearmind Medicine stock gains on Johns Hopkins trial approval By Investing.com - Investing.com Nigeria
Clearmind Medicine stock gains on Johns Hopkins trial approval - Investing.com
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts - The Manila Times
Clearmind Medicine Inc. Receives IRB Approval for Phase I/II Clinical Trial of CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Cash from financing activities of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Net income before discontinued operations of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Balance Sheet – LS:A427B1 - TradingView
Price to earnings ratio of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Dividends – LS:A427B1 - TradingView
Clearmind Medicine Inc. Earnings and Revenue – LS:A427B1 - TradingView
CMND News | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Will Clearmind Medicine (NASDAQ:CMND) Spend Its Cash Wisely? - Sahm
Clearmind Medicine to implement 1-for-10 reverse share split - MSN
Clearmind Medicine stock tumbles on reverse share split plan By Investing.com - Investing.com Nigeria
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings - Benzinga
Clearmind Medicine stock tumbles on reverse share split plan - Investing.com
Clearmind Medicine to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
they’re doing it for the hell of it. - Moomoo
Clearmind Medicine to implement 1-for-10 reverse stock split - Investing.com
Clearmind Medicine Inc. Announces 1-for-10 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine announces 1-for-10 reverse share split - marketscreener.com
Clearmind Medicine Announces 1-for-10 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-For-10 Reverse Share Split - TradingView
Clearmind Medicine to Study MEAI with Tirzepatide for Weight Management - geneonline.com
$Clearmind Medicine (CMND.US)$[Lol][Lol][Lol] - Moomoo
Clearmind signs research deal to study obesity drug combination By Investing.com - Investing.com Australia
Clearmind signs research deal to study obesity drug combination - Investing.com UK
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND) - Yahoo Finance
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications - The Manila Times
Clearmind Medicine CEO Dr. Adi Zuloff-Shani Participates in Psychedelic Medicine Coalition Federal Policy Summit - Quiver Quantitative
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. - The Manila Times
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Number of shareholders of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
TradingKey - TradingKey
Clearmind doses two more patients in alcohol disorder trial - Investing.com UK
Clearmind Medicine Treats 20 Participants in CMND-100 Alcohol Use Disorder Trial - geneonline.com
20 patients treated in Clearmind (Nasdaq: CMND) Phase I/IIa AUD study - Stock Titan
Clearmind doses two more patients in alcohol disorder trial By Investing.com - Investing.com Nigeria
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - The Manila Times
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):